Diakonos Oncology Corporation

This phase 2 trial tests whether adding DOC1021, a personalized dendritic cell vaccine, to standard treatment (surgery, chemo, radiation) improves survival in adults newly diagnosed with glioblastoma. About 180 participants will be randomly assigned to receive the vaccine plus st…

This study tests a new treatment called DOC1021 for people with advanced melanoma that has not responded to standard therapy. DOC1021 is a personalized vaccine made from a patient's own blood and tumor cells, designed to teach the immune system to attack the cancer. The trial wil…